Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
PM Abe Vows to Forge New System to Accelerate Mixed Care
Prime Minister Shinzo Abe pledged on June 10 to create a more flexible framework for the mixed use of publicly insured and uninsured healthcare services in Japan as part of his administration’s drive to ease what he terms “bedrock regulations.”…
To read the full story
Related Article
- Chuikyo Approves Draft Framework for Patient-Initiated Mixed Care; Will Establish Evaluation Council by Next Spring
October 2, 2015
- MHLW to Seek “Candidate Drug Lists” for Patient-Initiated Mixed Care from Medical Societies
July 9, 2015
- Regulatory Reform Proposal Including Expansion of Mixed Care Use Submitted to Prime Minister
June 16, 2014
- MHLW to Seek Opinions on Abe’s New Mixed Care Plan from Advisory Panels
June 11, 2014
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…